No Data
No Data
CH Biotech Ser (08037): Xu Haiyin resigns as non-executive director.
Ch Biotech Ser (08037) announced that Ms. Xu Haiyin has resigned as a non-executive director of the company, effective from 202...
Ch Biotech Ser (08037): Guo Yuantao has been appointed as an independent non-executive director.
Ch Biotech Ser (08037) announced that Guo Yuantao has been appointed as an independent non-executive director, as well as a member of the audit committee, nomination committee, and remuneration committee, effective immediately following the annual general meeting of shareholders.
ch biotech ser announced clinical trial results at the American ASCO 2024 annual meeting.
CH Biotech Ser (08037) announced that its indirectly non-wholly-owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., presented the results of Phase I clinical study on LY007 cell injection (a new autologous chimeric antigen receptor T-cell therapeutic product targeting CD20) for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in the form of a poster exhibition. It is reported that diffuse large B-cell lymphoma (DLBCL) (LBC
ch biotech ser (08037) announced the clinical trial results at the 2024 annual meeting of the American Society of Clinical Oncology.
Zhìtōng Cáijīng APP reports that CH Biotech Ser (08037) released an announcement that its indirectly non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., showcased the results of its Phase I clinical trial of LY007 cell injection (a new autologous chimeric antigen receptor T cell therapy product targeting CD20) in patients with relapsed/refractory B cell non-Hodgkin's lymphoma (B-NHL) at the American Society of Clinical Oncology (ASCO) 2024 annual meeting in the form of a poster presentation. It is reported that diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive, heterogeneous, and common subtypes of B-cell NHL, accounting for approximately 40% of cases in China.
China Biotechnology Services (08037) guarantees Shanghai Longyao
China Biotechnology Service (08037) announced that Shanghai Longyao Biotechnology, an indirect non-wholly-owned subsidiary of the company, has...
China Biotechnology Services (08037.HK) intends to appoint Guo Yuantao as an independent non-executive director
Gelonghui, May 13 | China Biotechnology Service (08037.HK) announced that since He Junjie plans to spend more time on other business and personal matters, Dr. Ho will retire as an independent non-executive director of the company and a member of the Audit Committee, Nomination Committee and Remuneration Committee starting at the end of the company's next annual general meeting of shareholders. The board of directors has proposed the election and appointment of Guo Yuantao as an independent non-executive director. The relevant ordinary resolution will be submitted at the Annual General Meeting of Shareholders for shareholders' consideration and approval. If the proposal is approved for appointment at the Annual General Meeting of Shareholders, Guo Yuantao will act as an independent partner
No Data